AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7597608 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely with sodium sulfate (47 patients)
Number of subjects: 100
Study 7597608 — intervention group
Group type: COMPARATOR
Intervention: Golytely without sodium sulfate (49 patients)
Number of subjects: 100
Study 7597608 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely with sodium sulfate
Number of subjects: 100
Study 7597608 — intervention group
Group type: COMPARATOR
Intervention: Golytely without sodium sulfate
Number of subjects: 100
Study 2193629 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/d
Number of subjects: 73
Study 2193629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 153862 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide treatment for 4 weeks
Number of subjects: 0
Study 153862 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide treatment for 1 week
Number of subjects: 0
Study 30987164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone treatment
Number of subjects: 25
Study 30987164 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma miRNA signature
Number of subjects: 25
Study 28692170 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of LNG-IUS after late first-trimester MTOP
Number of subjects: 159
Study 28692170 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUS after late first-trimester MTOP
Number of subjects: 159
Study 28692170 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate insertion of LNG-IUS after second-trimester MTOP
Number of subjects: 159
Study 28692170 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUS after second-trimester MTOP
Number of subjects: 159
Study 28692170 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate and delayed insertion of LNG-IUS
Number of subjects: 159
Study 25708147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1 gm at weeks 0 and 2)
Number of subjects: 28
Study 25708147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23072513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cessation advice report and progress report
Number of subjects: 6697
Study 23072513 — intervention group
Group type: COMPARATOR
Intervention: Standard non-tailored information
Number of subjects: 6697
Study 21403073 — intervention group
Group type: EXPERIMENTAL
Intervention: Early percutaneous tracheotomy
Number of subjects: 216
Study 21403073 — intervention group
Group type: COMPARATOR
Intervention: Prolonged intubation
Number of subjects: 216
Study 19538233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/low-carbohydrate meal
Number of subjects: 10
Study 19538233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI meal
Number of subjects: 10
Study 19538233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI meal
Number of subjects: 10
Study 19538233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie meal
Number of subjects: 10
Study 19538233 — intervention group
Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 10
Study 17305271 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric hearing loss (more than 10 dB difference between ears)
Number of subjects: 429
Study 17305271 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural difference in hearing threshold level
Number of subjects: 429
Study 17305271 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 429
Study 17305271 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, handedness, and sex
Number of subjects: 429
Study 17305271 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ear's hearing threshold level
Number of subjects: 429
Study 15370684 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% ethanol solution
Number of subjects: 10
Study 15370684 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ethanol solution
Number of subjects: 10
Study 15370684 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% ethanol solution
Number of subjects: 10
Study 15370684 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 10
Study 15370684 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 10
Study 15370684 — intervention group
Group type: EXPERIMENTAL
Intervention: Whisky
Number of subjects: 10
Study 15370684 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 5.5% (w/v)
Number of subjects: 10
Study 15370684 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 11.4% (w/v)
Number of subjects: 10
Study 15370684 — intervention group
Group type: COMPARATOR
Intervention: Water (500 mL)
Number of subjects: 10
Study 15370684 — intervention group
Group type: COMPARATOR
Intervention: Water (250 mL)
Number of subjects: 10
Study 11867933 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (EHDP) therapy
Number of subjects: 22
Study 11867933 — intervention group
Group type: COMPARATOR
Intervention: Parathyroidectomy (PTX)
Number of subjects: 22
Study 10221416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg once daily (q.i.d.)
Number of subjects: 215
Study 10221416 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily (b.i.d.)
Number of subjects: 215
Study 8657840 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg PO)
Number of subjects: 36
Study 8657840 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine (0.5 mg IV)
Number of subjects: 36
Study 8657840 — intervention group
Group type: COMPARATOR
Intervention: glycopyrrolate (0.2 mg IV)
Number of subjects: 36
Study 2110943 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g L-ascorbic acid
Number of subjects: 20
Study 2110943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6772045 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition preoperatively (group 1)
Number of subjects: 3
Study 6772045 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition postoperatively (group 2)
Number of subjects: 3
Study 6772045 — intervention group
Group type: COMPARATOR
Intervention: Fasting until 3 h after surgical intervention (group 3)
Number of subjects: 3
Study 31538372 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic‐Release Oral System Methylphenidate (OROS‐MPH)
Number of subjects: 134
Study 31538372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 30387461 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone ointment
Number of subjects: 60
Study 30387461 — intervention group
Group type: COMPARATOR
Intervention: Water-based gel (Control)
Number of subjects: 60
Study 26955179 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 50
Study 26955179 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 50
Study 24460827 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS with SMS reminders
Number of subjects: 0
Study 24460827 — intervention group
Group type: COMPARATOR
Intervention: DOTS (control group, no SMS intervention)
Number of subjects: 0
Study 21987042 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron
Number of subjects: 150
Study 21987042 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone (Control)
Number of subjects: 150
Study 20429978 — intervention group
Group type: EXPERIMENTAL
Intervention: SARMA software
Number of subjects: 29
Study 20429978 — intervention group
Group type: COMPARATOR
Intervention: Other methods (letter and direct invitation by a practice nurse)
Number of subjects: 29
Study 17187983 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 173
Study 17187983 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 173
Study 14706049 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II type 1 receptor blockers (ARBs)
Number of subjects: 3
Study 12324291 — intervention group
Group type: EXPERIMENTAL
Intervention: L-796568 (375 mg/d)
Number of subjects: 20
Study 12324291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9750733 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 26
Study 8151001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate sustained release tablets, dosages titrated from 30 mg/day up to a maximum of 120 mg/day.
Number of subjects: 0
Study 3072354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 161
Study 3072354 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg
Number of subjects: 161
Study 3072354 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg plus codeine 60 mg
Number of subjects: 161
Study 3072354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 29576114 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDHT) using oesophageal Doppler monitor, aimed to maintain stroke volume, mean arterial pressure >70 mm Hg, and cardiac index ≥2.5 litres min‐1 m‐2
Number of subjects: 450
Study 29576114 — intervention group
Group type: COMPARATOR
Intervention: Control group with intraoperative fluids based on traditional principles
Number of subjects: 450
Study 29576114 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDHT)
Number of subjects: 450
Study 28526466 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group (n=60)
Number of subjects: 180
Study 28526466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational group (n=60)
Number of subjects: 180
Study 28526466 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple group (n=60)
Number of subjects: 180
Study 25588353 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) in LCIG-naïve patients (N = 29)
Number of subjects: 62
Study 25588353 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG) in continuing-LCIG patients (N = 33)
Number of subjects: 62
Study 25588353 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impression-Improvement scale rating for both groups
Number of subjects: 62
Study 23660512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle (ILS)
Number of subjects: 724
Study 23660512 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 724
Study 23660512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 724
Study 20185731 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 24
Study 20185731 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (CSII)
Number of subjects: 24
Study 20185731 — intervention group
Group type: EXPERIMENTAL
Intervention: CIPII
Number of subjects: 24
Study 20185731 — intervention group
Group type: COMPARATOR
Intervention: CSII
Number of subjects: 24
Study 18232724 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (maximum dose of 3000 mg/day)
Number of subjects: 40
Study 18232724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16801586 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention to increase physical activity over 3 years.
Number of subjects: 2950
Study 12756090 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP plus HIFU
Number of subjects: 271
Study 12756090 — intervention group
Group type: COMPARATOR
Intervention: HIFU
Number of subjects: 271
Study 10762579 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir (10 mg twice daily for 5 days)
Number of subjects: 27
Study 10762579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8985910 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-ms gap during fixation
Number of subjects: 4
Study 8985910 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-ms gap during pursuit
Number of subjects: 4
Study 8985910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate gap durations during fixation
Number of subjects: 4
Study 8985910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate gap durations during pursuit
Number of subjects: 4
Study 8985910 — intervention group
Group type: COMPARATOR
Intervention: No gap
Number of subjects: 4
Study 8103820 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal-antibody-purified FVIII concentrates
Number of subjects: 60
Study 8103820 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-purity FVIII concentrates
Number of subjects: 60
Study 3529800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 30
Study 3529800 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 30
Study 3529800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tranexamic acid and naproxen
Number of subjects: 30
Study 30290903 — intervention group
Group type: EXPERIMENTAL
Intervention: COPP/ABVD
Number of subjects: 2952
Study 30290903 — intervention group
Group type: EXPERIMENTAL
Intervention: bBEACOPP
Number of subjects: 2952
Study 30290903 — intervention group
Group type: EXPERIMENTAL
Intervention: eBEACOPP
Number of subjects: 2952
Study 30290903 — intervention group
Group type: EXPERIMENTAL
Intervention: 4+4
Number of subjects: 2952
Study 30290903 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 2952
Study 27412789 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-receptor antagonist haloperidol
Number of subjects: 20
Study 27412789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27412789 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 20
Study 25941810 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 calcium-fortified cereal bars daily (total of 400 mg calcium/day)
Number of subjects: 35
Study 25941810 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 35
Study 25941810 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 calcium-fortified cereal bars daily
Number of subjects: 35
Study 24697033 — intervention group
Group type: EXPERIMENTAL
Intervention: JJ stent left in situ (Group I)
Number of subjects: 54
Study 24697033 — intervention group
Group type: COMPARATOR
Intervention: No stent (Group II)
Number of subjects: 54
Study 21685206 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (HBR)
Number of subjects: 89
Study 21685206 — intervention group
Group type: COMPARATOR
Intervention: Day hospital rehabilitation (DHR)
Number of subjects: 89
Study 17559359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, bismuth subcitrate, metronidazole, and amoxicillin (LBMA)
Number of subjects: 0
Study 17559359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, bismuth subcitrate, tetracycline, and amoxicillin (LBTA)
Number of subjects: 0
Study 17559359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, bismuth subcitrate, metronidazole, and tetracycline (LBMT)
Number of subjects: 0
Study 17559359 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17128840 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dexpanthenol and zinc oxide ointment
Number of subjects: 46
Study 17128840 — intervention group
Group type: COMPARATOR
Intervention: Ointment base
Number of subjects: 46
Study 14618470 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg oestradiol implants, replaced every 4 months
Number of subjects: 34
Study 14618470 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 11069229 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) daily for 3 months, followed by IFN 3 times weekly (TIW) for 12 months (group A)
Number of subjects: 95
Study 11069229 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) 3 times weekly (TIW) for 18 months (group B)
Number of subjects: 95
Study 9197048 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-teaching materials at the hardest readability level
Number of subjects: 0
Study 9197048 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-teaching materials at the easiest readability level
Number of subjects: 0
Study 9197048 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-teaching materials at various readability levels
Number of subjects: 0
Study 1439406 — intervention group
Group type: EXPERIMENTAL
Intervention: Test compound
Number of subjects: 20
Study 1439406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3969937 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc intake of 18.5 mg/day for two consecutive weeks
Number of subjects: 9
Study 3969937 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc intake of 3.5 mg/day above the RDA for men
Number of subjects: 9
Study 31450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching
Number of subjects: 137
Study 31450870 — intervention group
Group type: COMPARATOR
Intervention: No endometrial scratching (control)
Number of subjects: 137
Study 31450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching with long agonist protocol
Number of subjects: 137
Study 31450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching with antagonist protocol
Number of subjects: 137
Study 31450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously failed IVF
Number of subjects: 137
Study 31450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with long agonist protocol
Number of subjects: 137
Study 31450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with antagonist protocol
Number of subjects: 137
Study 31450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of embryos
Number of subjects: 137
Study 31450870 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of blastocysts
Number of subjects: 137
Study 29384859 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment
Number of subjects: 64
Study 29384859 — intervention group
Group type: COMPARATOR
Intervention: Simple cleaning regimen
Number of subjects: 64
Study 26519996 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher beta-blocker dose
Number of subjects: 2331
Study 26519996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower heart rate
Number of subjects: 2331
Study 25317898 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patients
Number of subjects: 47286
Study 25317898 — intervention group
Group type: COMPARATOR
Intervention: Inactive patients
Number of subjects: 47286
Study 25317898 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 47286
Study 25317898 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity before rehabilitation
Number of subjects: 47286
Study 25317898 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities and age
Number of subjects: 47286
Study 22505395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 375
Study 22505395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 20569035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sustained hamstring stretching + 60 seconds of sciatic nerve slider technique for each leg
Number of subjects: 8
Study 20569035 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sustained hamstring stretching
Number of subjects: 8
Study 18070842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 18070842 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 18070842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15683472 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-guided ablation (group 1, n = 30)
Number of subjects: 60
Study 15683472 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy guidance ablation (group 2, n = 30)
Number of subjects: 60
Study 12428179 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with arginine and fiber (group I)
Number of subjects: 47
Study 12428179 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula (group II)
Number of subjects: 47
Study 10325501 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HPR (two 100-mg capsules daily for 3 weeks)
Number of subjects: 37
Study 10325501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules daily for 3 weeks)
Number of subjects: 37
Study 8519723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine infusion (i.v.P) at 35 mg
Number of subjects: 37
Study 8519723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine infusion (i.v.P) at higher doses (50 mg or 75 mg)
Number of subjects: 37
Study 1422748 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour duplex ultrasonography
Number of subjects: 65
Study 1422748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-generated run-off (PGR)
Number of subjects: 65
Study 1422748 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic angiography
Number of subjects: 65
Study 1422748 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive assessment (duplex examination)
Number of subjects: 65
Study 1422748 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 65
Study 1422748 — intervention group
Group type: EXPERIMENTAL
Intervention: PGR
Number of subjects: 65
Study 6320943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose corticotrophin
Number of subjects: 21
Study 6320943 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 21
Study 6320943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (corticotrophin and placebo)
Number of subjects: 21
Study 6320943 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplanar radiography
Number of subjects: 21
Study 6320943 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck movements
Number of subjects: 21
Study 31190757 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive Interdisciplinary Self-Management (PRISMA) program, 6-month duration, two group meetings about T2DM guided by care providers.
Number of subjects: 108